Advanced Biomed Launches A+PerfusC™ 3D Cell Culture Platform for Enhanced Drug Discovery and Precision Medicine
Key Insights
Advanced Biomed Inc. (search) has launched the A+PerfusC™ (search) system, a compact all-in-one perfusion 3D cell culture incubator designed to replicate human physiological conditions in vitro.
The platform supports up to 12 days of continuous, hands-free culture with automated perfusion and environmental control, reducing human error and contamination risks.
The system can generate up to 4,800 tumor (search) spheroids per plate across 8 independent channels, enabling high-throughput drug screening applications.
Advanced Biomed Inc. (search) (Nasdaq: ADVB) has announced the launch of its A+PerfusC™ (search) system, a compact, all-in-one perfusion 3D cell culture incubator designed to replicate human physiological conditions in vitro. The Taiwan-based biotechnology company's new platform addresses critical limitations in traditional static cell culture methods that often compromise cell growth, viability, and reproducibility.
Platform Capabilities and Design
The A+PerfusC™ (search) platform integrates automated perfusion with environmental control in a compact format that can be mounted directly onto a microscope for real-time observation. The system supports up to 12 days of continuous, hands-free culture, significantly reducing the risk of human error and contamination compared to conventional methods.
Key technical specifications include:
- 8 independent channels per patient source per plate
- 600 tumor spheroids per row for one patient
- 4,800 tumor spheroids per plate
- Easy transfer capability into 96 or 384 well plates for high-throughput drug screening
- Direct mounting compatibility with microscopy platforms
- Expandable control platform supporting up to four incubators (under development)
By maintaining uniform nutrient delivery and preventing waste accumulation, the platform promotes spheroid and organoid formation, enhancing cell viability, growth, and drug response predictability.
Addressing Traditional Culture Limitations
Dr. Yi Lu, CEO of Advanced Biomed, explained the technological advantages: "Traditional static cell culture often leads to uneven nutrient delivery and waste buildup, compromising cell growth, viability, and reproducibility. Notably, in certain high-density culture scenarios, particularly within multi-microwell 3D culture devices, metabolic waste can rapidly accumulate inside the micro-grooves, requiring more frequent medium replacement which can be labor-intensive to preserve culture quality."
The company's 3D culture system addresses these challenges by evenly delivering nutrients and clearing waste, reducing cellular stress, boosting long-term viability, and more accurately mimicking human tissue complexity for improved drug response and disease modeling.
Market Applications and Commercialization
Potential applications for the A+PerfusC™ (search) system span multiple research areas including personalized oncology research, in vitro drug screening, regenerative medicine, organoid studies, and stem cell research. The platform's design supports the growing demand for more physiologically relevant cell culture models in drug discovery and development.
The A+PerfusC™ (search) system and its 3D culture plate consumables have passed internal testing and validation with design finalized. Advanced Biomed is currently advancing mass-production development, with commercialization planned following completion of mass-production development and establishment of quality control standards.
Market Growth Projections
According to Mordor Intelligence, the global 3D cell culture market was valued at $2.32 billion in 2025 and is projected to exceed $4.71 billion by 2030, representing a compound annual growth rate of over 15.6%. This growth trajectory reflects increasing recognition of the limitations of traditional 2D cell culture methods and the need for more physiologically relevant in vitro models.
Future Development Plans
Advanced Biomed plans to scale up the A+PerfusC™ (search) system for high-throughput use and integrate imaging with AI-driven analytics. These enhancements aim to accelerate tumor (search) profiling, refine cell therapy protocols, and advance personalized treatment development.
The company operates through subsidiaries in Taiwan, Hong Kong, and Mainland China, and has developed a proprietary microfluidic platform that integrates semiconductor and biotechnology for advanced circulating tumor (search) cell detection, enrichment, and analysis.